Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MAT 9001

Drug Profile

MAT 9001

Alternative Names: MAT-9001

Latest Information Update: 27 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Matinas BioPharma
  • Class Antihyperlipidaemics; Omega 3 fatty acids
  • Mechanism of Action Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Hypertriglyceridaemia
  • No development reported Dyslipidaemias

Most Recent Events

  • 13 Aug 2019 Matinas BioPharma plans the pharmacodynamics phase II ENHANCE-IT comparative trial of MAT 9001 and Vascepa® for Hypertriglyceridaemia in USA (PO, Capsule) in February 2020 (NCT04177680)
  • 13 Aug 2019 Matinas BioPharma completes a 28-day comparative bridging toxicology study of MAT 9001
  • 13 Aug 2019 Matinas BioPharma plans a comparative clinical bridging bioavailability study for Hypertriglyceridaemia in Q4 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top